Joon Hyuk Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joon Hyuk Choi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jin Lee
Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
4 shared publications - Nae-Yun Heo
Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
4 shared publications - Seung Ha Park
Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
4 shared publications - Tae Oh Kim
Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
4 shared publications - Yong Eun Park
Division of Gastroenterology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
4 shared publications - Jongha Park
Division of Gastroenterology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
3 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 307-313
Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Objectives: Tegoprazan is a novel potassium-competitive acid blocker that rapidly suppresses acid secretion. This study aimed to evaluate the efficacy of tegoprazan 50 mg compared with esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms.Methods: This double-blind, randomized, active-control study was conducted to compare the efficacy of tegoprazan 50 mg and esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. The primary endpoint was the percentage of nocturnal heartburn-free days over 2 weeks. The secondary endpoint was the percentage of patients who experienced relief from nocturnal heartburn within 24 h of the first dose. Additionally, the time to the first nocturnal heartburn-free interval was compared between the two groups.Results: Of 160 patients, 149 were included in the final analysis. The percentage of nocturnal heartburn-free days over 2 weeks was not inferior to that with esomeprazole (58.2% vs. 54.5%, p=0.001). The percentage of patients without nocturnal heartburn for 24 h was higher in the tegoprazan group, although the difference was not statistically significant. The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant.Conclusions: Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may provide more rapid relief from nocturnal heartburn symptoms.
- 10 September 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (3) , 307-313
Open AccessShort-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Objectives: Tegoprazan is a novel potassium-competitive acid blocker that rapidly suppresses acid secretion. This study aimed to evaluate the efficacy of tegoprazan 50 mg compared with esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms.Methods: This double-blind, randomized, active-control study was conducted to compare the efficacy of tegoprazan 50 mg and esomeprazole 20 mg in patients with non-erosive reflux disease and nocturnal heartburn symptoms. The primary endpoint was the percentage of nocturnal heartburn-free days over 2 weeks. The secondary endpoint was the percentage of patients who experienced relief from nocturnal heartburn within 24 h of the first dose. Additionally, the time to the first nocturnal heartburn-free interval was compared between the two groups.Results: Of 160 patients, 149 were included in the final analysis. The percentage of nocturnal heartburn-free days over 2 weeks was not inferior to that with esomeprazole (58.2% vs. 54.5%, p=0.001). The percentage of patients without nocturnal heartburn for 24 h was higher in the tegoprazan group, although the difference was not statistically significant. The time to the first nocturnal heartburn-free interval was shorter with tegoprazan than with esomeprazole (2.0 days vs. 2.5 days, p=0.529); however, the difference was not significant.Conclusions: Tegoprazan demonstrated non-inferiority to esomeprazole with respect to nocturnal heartburn-free days and may provide more rapid relief from nocturnal heartburn symptoms.
- Open Access
- 10 March 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (1) , 73-78
Clinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study
Objectives: Tegoprazan is an alternative to proton pump inhibitors (PPIs). This study evaluated the occurrence of upper gastrointestinal (GI) and cardiovascular (CV) complications in patients with ischemic heart disease undergoing antiplatelet therapy after percutaneous coronary intervention (PCI) who were treated with tegoprazan or PPIs. Methods: Data from 604 patients who received antiplatelet therapy with tegoprazan or PPIs for >6 months after PCI between March 2019 and November 2023 were retrospectively analyzed. The primary GI endpoints were symptomatic gastroduodenal ulcers and upper GI bleeding, while the primary CV endpoints comprised major adverse cardiac events (MACEs), nonfatal myocardial infarction (MI), target vessel revascularization, and death from CV-related causes. Results: Among the 604 patients, 265 received tegoprazan and 339 received PPIs. During a mean follow-up of 17 months, seven patients experienced a GI event (0.4% with tegoprazan vs. 1.8% with PPIs; p=0.112) and 12 experienced MACEs (1.1% with tegoprazan vs. 2.7% with PPIs; p=0.183). Subgroup analysis indicated that target vessel revascularization occurred in six patients, with event rates of 0.8% (n=2) for tegoprazan and 1.2% (n=4) for PPIs (p=0.598). Tegoprazan was associated with similar rates of nonfatal MI (0.8% vs. 2.4%; p=0.125) and death from CV-related causes (0.4% vs. 0%; p=0.258) as PPIs. Conclusions: There were no significant differences in GI- or CV-related complications between patients treated with tegoprazan and those treated with PPIs.
- 10 March 2026
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 26 (1) , 73-78
Open AccessClinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study
Objectives: Tegoprazan is an alternative to proton pump inhibitors (PPIs). This study evaluated the occurrence of upper gastrointestinal (GI) and cardiovascular (CV) complications in patients with ischemic heart disease undergoing antiplatelet therapy after percutaneous coronary intervention (PCI) who were treated with tegoprazan or PPIs. Methods: Data from 604 patients who received antiplatelet therapy with tegoprazan or PPIs for >6 months after PCI between March 2019 and November 2023 were retrospectively analyzed. The primary GI endpoints were symptomatic gastroduodenal ulcers and upper GI bleeding, while the primary CV endpoints comprised major adverse cardiac events (MACEs), nonfatal myocardial infarction (MI), target vessel revascularization, and death from CV-related causes. Results: Among the 604 patients, 265 received tegoprazan and 339 received PPIs. During a mean follow-up of 17 months, seven patients experienced a GI event (0.4% with tegoprazan vs. 1.8% with PPIs; p=0.112) and 12 experienced MACEs (1.1% with tegoprazan vs. 2.7% with PPIs; p=0.183). Subgroup analysis indicated that target vessel revascularization occurred in six patients, with event rates of 0.8% (n=2) for tegoprazan and 1.2% (n=4) for PPIs (p=0.598). Tegoprazan was associated with similar rates of nonfatal MI (0.8% vs. 2.4%; p=0.125) and death from CV-related causes (0.4% vs. 0%; p=0.258) as PPIs. Conclusions: There were no significant differences in GI- or CV-related complications between patients treated with tegoprazan and those treated with PPIs.
- Open Access
- 10 March 2024
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 24 (1) , 58-63
Comparison of Endoscopic Submucosal Dissection With Endoscopic Mucosal Resection After Circumferential Precutting to Treat Gastric Adenomas ≤15 mm
Objectives: Endoscopic submucosal dissection (ESD) is a widely used approach for the resection of superficial gastric neoplastic lesions. Endoscopic mucosal resection (EMR) is acceptable for lesions <10–15 mm in size. Herein, we compared the clinical outcomes of ESD with those of EMR after circumferential precutting (EMR-P) for gastric adenomas ≤15 mm.Methods: We retrospectively analyzed the data of 213 patients with 228 gastric adenomas ≤15 mm in size who were treated endoscopically at a single tertiary hospital in Korea between November 2018 and October 2022. We evaluated the complete endoscopic resection rate, recurrence rate, procedurer-elated complications, and procedure time according to the procedure used.Results: Among the 228 gastric adenomas, 49 were treated with EMR-P and 179 with ESD. The histological complete resection rate was higher in the ESD group than in the EMR-P group (87% vs. 57%, p<0.001). No significant between-group differences were observed in endoscopic en bloc resection rates (ESD vs. EMR-P, 96% vs. 90%; p=0.081). The procedure time was significantly shorter in the EMR-P group than in the ESD group (28.9±19.7 min vs. 8.8±5.9 min, p<0.001). The local recurrence rate in patients with histologically incomplete resection did not differ between the two groups (ESD vs. EMR-P, 8.7% vs. 9.5%; p=0.924).Conclusions: For gastric adenomas ≤15 mm, EMR-P may be the preferable treatment method considering the en bloc resection rate, procedure time, and local recurrence rate. However, considering the complete resection rate, ESD is recommended as the treatment of choice for high-grade adenomas and early gastric cancer lesions.
- 10 March 2024
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 24 (1) , 58-63
Open AccessComparison of Endoscopic Submucosal Dissection With Endoscopic Mucosal Resection After Circumferential Precutting to Treat Gastric Adenomas ≤15 mm
Objectives: Endoscopic submucosal dissection (ESD) is a widely used approach for the resection of superficial gastric neoplastic lesions. Endoscopic mucosal resection (EMR) is acceptable for lesions <10–15 mm in size. Herein, we compared the clinical outcomes of ESD with those of EMR after circumferential precutting (EMR-P) for gastric adenomas ≤15 mm.Methods: We retrospectively analyzed the data of 213 patients with 228 gastric adenomas ≤15 mm in size who were treated endoscopically at a single tertiary hospital in Korea between November 2018 and October 2022. We evaluated the complete endoscopic resection rate, recurrence rate, procedurer-elated complications, and procedure time according to the procedure used.Results: Among the 228 gastric adenomas, 49 were treated with EMR-P and 179 with ESD. The histological complete resection rate was higher in the ESD group than in the EMR-P group (87% vs. 57%, p<0.001). No significant between-group differences were observed in endoscopic en bloc resection rates (ESD vs. EMR-P, 96% vs. 90%; p=0.081). The procedure time was significantly shorter in the EMR-P group than in the ESD group (28.9±19.7 min vs. 8.8±5.9 min, p<0.001). The local recurrence rate in patients with histologically incomplete resection did not differ between the two groups (ESD vs. EMR-P, 8.7% vs. 9.5%; p=0.924).Conclusions: For gastric adenomas ≤15 mm, EMR-P may be the preferable treatment method considering the en bloc resection rate, procedure time, and local recurrence rate. However, considering the complete resection rate, ESD is recommended as the treatment of choice for high-grade adenomas and early gastric cancer lesions.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (49) , e412
Blood Concentrations of Lead, Cadmium, and Mercury Are Associated With Alcohol-Related Liver Disease
Kim JH, et al. J Korean Med Sci. 2023 Dec;38:e412. https://doi.org/10.3346/jkms.2023.38.e412
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (49) , e412
Open AccessBlood Concentrations of Lead, Cadmium, and Mercury Are Associated With Alcohol-Related Liver Disease
Kim JH, et al. J Korean Med Sci. 2023 Dec;38:e412. https://doi.org/10.3346/jkms.2023.38.e412